Active T rosettes, human autologous T rosettes, OKT8 and OKT4 cells, Con A-induced suppressive activity, and autoantibodies: Clinical correlations

The immune system during the pre‐cancer and the early cancer period. IL‐2 production by PBL from post‐menopausal women with and without endometrial carcinoma

“…In view of these results, we are looking into the possibility that suppressor T-cells contribute to the IL-2 defect of EC patients. It is well established that suppressor cells can be activated in vitro by Con-A either to directly suppress T cell activation or to produce suppressor factors (Schandene, 1983). A small proportion of Con-A-activated T-cells form rosettes with autologous and allogeneic human red blood cells (designated autorosette-forming cells-ARFC) (Kumagai et al, 1981;Sakane et al, 1981;Takada er al., 1983;Nalet and Fournier, 1983).…”

Regulatory roles of T mu and T gamma cells in the collaborative cellular initiation of the extrinsic coagulation pathway by bacterial lipopolysaccharide.

“…OKT4 monoclonal antibody reacted with 60% of the T cell population and these cells were required for the optimal development of the cytotoxic cell in cell-mediated lympholysis, induction of B cell differentiation, proliferation, and immunoglobulin synthesis in a pokeweed mitogen-driven system and the production of helper factors (39 (55)(56)(57). Whether aberrations in T subsets functional in the PCA response may occur is not known yet.…”

T Lymphocyte Study in Sickle Cell Anaemia by Means of Rosetting Techniques

“…Both clinical and experi mental studies suggest that the active rosette-forming cells represent a subpopulation of peripheral T lym- phocytes which are more actively involved in cellular immunity than the total E rosette forming cells, so that active rosettes are a better reflection of T cell competence than the total percentage of T cells [6,10], Recent studies have shown correlation between active E rosettes and autologous rosettes and antigens de fined on peripheral lymphocytes by OKT8 and GKT4 monoclonal antibodies, respectively [1,9]. We suggest that T lymphocyte subpopulations must be further investigated in SCA patients and that the use of monoclonal antibodies will surely help to more accurately define in SCA the T cell subpopula tions giving additional evidence on the problems of immunocompetence noted in these patients.…”